Discussion stirs around XOMA Corporation (NASDAQ:XOMA) this week; here is what analysts are saying.

October 11, 2018 - By Vivian Park

XOMA Corporation (NASDAQ:XOMA) Logo

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

Among 2 analysts covering Xoma Corp (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Xoma Corp had 2 analyst reports since April 30, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Monday, April 30 by H.C. Wainwright. Wedbush maintained XOMA Corporation (NASDAQ:XOMA) on Monday, May 21 with “Buy” rating. Below is a list of XOMA Corporation (NASDAQ:XOMA) latest ratings and price target changes.

21/05/2018 Broker: Wedbush Rating: Buy New Target: $33.0000 Maintain
30/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0000 Maintain

The stock increased 7.85% or $1.17 during the last trading session, reaching $16.08. About 54,039 shares traded. XOMA Corporation (NASDAQ:XOMA) has declined 12.34% since October 11, 2017 and is downtrending. It has underperformed by 27.96% the S&P500.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $134.87 million. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It has a 8.54 P/E ratio. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

More news for XOMA Corporation (NASDAQ:XOMA) were recently published by: Globenewswire.com, which released: “XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte” on September 21, 2018. Nasdaq.com‘s article titled: “XOMA to Present at the Cantor Fitzgerald Healthcare Conference 2018 and the 2018 BIO Investor Forum” and published on September 27, 2018 is yet another important article.

XOMA Corporation (NASDAQ:XOMA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>